Kymera Therapeutics (KYMR) Shares Outstanding (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Shares Outstanding (Entity) of $82.2 million for Q1 2026, up 26.22% year-over-year from $65.1 million in Q1 2025, and up 1.06% quarter-over-quarter from $81.3 million in Q4 2025.
Kymera Therapeutics (KYMR) Shares Outstanding (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Shares Outstanding (Entity) for 8 consecutive years, with $82.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 26.22% year-over-year to $82.2 million; the TTM figure through Mar 2026 stood at $82.2 million (up 26.22% YoY), while the FY2025 annual figure was $81.3 million, up 25.32% from the prior year.
- Shares Outstanding (Entity) climbed to $82.2 million in Q1 2026 per KYMR's latest filing, from $81.3 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $82.2 million in Q1 2026 and bottomed at $51.7 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $62.3 million across 5 years, with a median of $61.4 million in 2024.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) climbed 0.99% — and 2026, when it rose 26.22%.
- Kymera Therapeutics' Shares Outstanding (Entity) stood at $55.0 million in 2022, then advanced by 0.99% to $55.6 million in 2023, then increased by 16.74% to $64.9 million in 2024, then climbed by 25.32% to $81.3 million in 2025, then advanced by 1.06% to $82.2 million in 2026.
- Business Quant data shows KYMR's Shares Outstanding (Entity) at $82.2 million in Q1 2026, $81.3 million in Q4 2025, and $71.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | 98.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 98.18 Mn |
| Mar 31, 2026 | 97.53 Mn |
| Dec 31, 2025 | 84.49 Mn |
| Sep 30, 2025 | 87.30 Mn |
| Jun 30, 2025 | 80.45 Mn |
| Mar 31, 2025 | 80.15 Mn |
| Dec 31, 2024 | 75.04 Mn |
| Sep 30, 2024 | 76.13 Mn |
| Jun 30, 2024 | 73.06 Mn |
| Mar 31, 2024 | 70.77 Mn |
| Dec 31, 2023 | 58.37 Mn |
| Sep 30, 2023 | 58.42 Mn |
| Jun 30, 2023 | 58.33 Mn |
| Mar 31, 2023 | 58.19 Mn |
| Dec 31, 2022 | 53.93 Mn |
| Sep 30, 2022 | 54.54 Mn |
| Jun 30, 2022 | 51.77 Mn |
| Mar 31, 2022 | 51.65 Mn |
| Dec 31, 2021 | 47.99 Mn |
| Sep 30, 2021 | 50.71 Mn |